Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparison

Autor: Cornelissen, Jan J. ^*, van der Holt, Bronno, Verhoef, Gregor E.G., van 't Veer, Mars B., van Oers, Marinus H.J., Schouten, Harry C., Ossenkoppele, Gert, Sonneveld, Pieter, Maertens, Johan, van Marwijk Kooy, Marinus, Schaafsma, Martijn R., Wijermans, Pierre W., Biesma, Douwe H., Wittebol, Shulamit, Voogt, Paul J., Baars, Joke W., Zachée, Pierre, Verdonck, Leo F., Löwenberg, Bob, Dekker, Adriaan W.

Publikováno v: In Blood 5 February 2009 113(6):1375-1382

Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study

Autor: Segeren, Christine M. ^*, Sonneveld, Pieter, van der Holt, Bronno, Vellenga, Edo, Croockewit, Alexandra J., Verhoef, Gregor E.G., Cornelissen, Jan J., Schaafsma, Martijn R., van Oers, Marinus H.J., Wijermans, Pierre W., Fibbe, Wim E., Wittebol, Shulamit, Schouten, Harry C., Kooy, Marinus van Marwijk, Biesma, Douwe H., Baars, Joke W., Slater, Rosalyn, Steijaert, Monique M.C., Buijt, Ivon, Lokhorst, Henk M.

Publikováno v: In Blood 15 March 2003 101(6):2144-2151

Bortezomib Induction and Maintenance Treatment Improves Survival In Patients With Newly Diagnosed Multiple Myeloma:Extended Follow-Up Of The HOVON-65/GMMG-HD4 Trial

Autor: Scheid, Christof, Holt, Bronno van der, Jarari, Laila el, Bertsch, Uta, Salwender, Hans, Zweegman, Sonja, Vellenga, Edo, Broyl, Annemiek, Blau, Igor Wolfgang, Weisel, Katja, Wittebol, Shulamit, Bos, Gerard M.J., Stevens, Marjan, Schmidt-Wolf, Ingo GH, Pfreundschuh, Michael, Hose, Dirk, Jauch, Anna, Velde, Helgi van de, Raymakers, Reinier, Schaafsma, Martyn Ronald, Kersten, Marie Jose, Kooy, Marinus van Marwijk, Duehrsen, Ulrich, Lindemann, Hans Walter, Wijermans, Pierre W., Lokhorst, Henk, Goldschmidt, H.

Publikováno v: Blood, 122(21), 404-404. American Society of Hematology
Scheid, C, Holt, B V D, Jarari, L E, Bertsch, U, Salwender, H, Zweegman, S, Vellenga, E, Broyl, A, Blau, I W, Weisel, K, Wittebol, S, Bos, G M J, Stevens, M, Schmidt-Wolf, I GH, Pfreundschuh, M, Hose, D, Jauch, A, Velde, H V D, Raymakers, R, Schaafsma, M R, Kersten, M J, Kooy, M V M, Duehrsen, U, Lindemann, H W, Wijermans, P W, Lokhorst, H & Goldschmidt, H 2013, ' Bortezomib Induction and Maintenance Treatment Improves Survival In Patients With Newly Diagnosed Multiple Myeloma:Extended Follow-Up Of The HOVON-65/GMMG-HD4 Trial ', Blood, vol. 122, no. 21, pp. 404-404 . < http://www.mendeley.com/research/bortezomib-induction-maintenance-treatment-improves-survival-patients-newly-diagnosed-multiple-myelo >

Background We investigated if bortezomib during induction and maintenance improves survival in newly diagnosed Multiple Myeloma (MM).\r\n\r\nMethods 827 eligible patients with newly diagnosed symptomatic MM were randomized to receive induction therap

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::5945042e0304df3c98b7ae1b83e8c231
https://research.vumc.nl/en/publications/cb2eeb05-41e7-40e3-8115-b33914e3438f

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.